NovaBiotics Wins Life Science Business Leadership Award
NovaBiotics Ltd, the Aberdeen-based, clinical-stage biotechnology company was awarded the Life Science Business Leadership Award at the Scottish Enterprise Life Sciences Annual Dinner on 6 February 2014 at the Edinburgh International Conference Centre.
The Life Science Business Leadership Award is presented to the business leader or management team who has significantly advanced their company in the previous year, with factors such as financing, partnerships, collaborations, achievement of milestones and growth being taken into consideration.
NovaBiotics’ CEO, Dr Deborah O’Neil, won the award for her leadership and vision which has been instrumental in the growth of NovaBiotics. After 11 years of work and 3 years of contract development, Deborah and her team secured an exclusive agreement with Taro Pharmaceuticals to license and co-develop the Company’s lead product Novexatin in August 2013, which is among the largest deals reached in the Scottish life science arena in recent years. NovaBiotics’ unique and ambitious strategy has also been recognised.
Dr O’Neil said: “I am proud of what NovaBiotics has achieved thus far and the Life Science Business Leadership Award reflects this. Our deal with Taro Pharmaceuticals is a huge success for the company and demonstrates industry confidence in our approach. By sticking to our business model and focusing on the results that our research was producing, we have created a solid foundation for our products and vision. Through all of this, we have been very fortunate to have been supported by organisations like the Scottish Enterprise, funding bodies, excellent, sector-specific mentors and a very talented team.”
The awards ceremony, hosted by Scottish Enterprise, recognises the success and achievements of Scotland’s internationally renowned life sciences sector in areas including innovation, investment, community engagement and collaboration. Scottish Enterprise identifies and exploits opportunities for Scotland's economic growth by supporting Scottish companies to compete, helping to build globally competitive sectors, attracting new investment and creating a world-class business environment.
Julia Brown, Director of Life and Chemical Sciences, Scottish Enterprise, said: “Congratulations to Dr O’Neil and to NovaBiotics. This is a fantastic achievement and the company’s continued success, including its international outlook, is very much testament to the innovation, drive and vision that Dr O’Neil demonstrates on a daily basis.”
Related News
-
News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel
A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to... -
News Protecting life-saving therapies: CPHI Online Podcast Series
The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.
-
News 2026 Outsourcing Outlook Update - pharma at a crossroads
The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ... -
News Roche maintains German investment commitment whilst rivals scale back
Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.
-
News Women in Pharma: The History of CPHI Women in Japan
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News EU drafts deal to end essential medicines shortage
European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.
-
News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg
The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th... -
News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026
CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.